We are excited to announce the addition of select genetic testing markers to the urinary hormone profiles – Complete Hormones and Essential Estrogens – done thru Genova Diagnostics Laboratory. Assessment of these select genomic markers (also known as SNPs) in conjunction with urine hormone testing, supports broadened clinical insight into women’s and men’s health concerns.
By evaluating hormones combined with your genetic SNP, you gain insight into an array of conditions affecting peri/menopausal and andropausal (male menopause) patients including anxiety and other mood shifts, cardiovascular disease, cardiometabolic syndrome, and bone health and hormone detoxification capacity. Once genomic predisposition is determined, you can target completely personalized treatment protocols to help lower disease risk and feel better.
Clinical indications for testing these SNPs include:
MTHFR—Methylenetetrahydrofolate reductase
- Low bone mineral density and/or fracture risk
- Potential risk of all cancers
- Low levels of B vitamins, especially folate
- Risk for cardiovascular disease and stroke
COMT—Catechol-O-Methyltransferase
- Mood disorders
- Chronic, high levels of stress
- Increased risk for fracture
- High or imbalanced estrogen levels especially 4-hydroxyestrogen
VDR—Vitamin D Receptor
- Autoimmune diseases
- Metabolic syndrome
- Cancer risk and progression
- Osteopenia/osteoporosis
CYP1B1—Cytochrome P450 1B1
- Increased risk for cancers in specific populations
- Exposure-specific cancers